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There is evidence that an aberrant tumour microenviron-
ment (TME) facilitates cancer development, progression,
and responses to treatment. While many of the mecha-
nisms underlying the phenotype and cancer-promoting
behaviour of the TME are unknown, epigenetic mecha-
nisms in cancer cells and the TME are thought to play
important roles. As a result, cancer profiling strategies for
drug and biomarker development require a thorough un-
derstanding of both the epithelial tissue compartment and
the TME. This review discusses recent advances in our
understanding of how cancer epithelial cells interact with
their microenvironment and how this knowledge can be
exploited clinically.
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Breast cancer tissues contain genetic and epigenetic changes
that result in altered epithelial cell structure and function.
Epigenetic regulation is deﬁned as any heritable modiﬁca-
tions in gene expression and chromatin structure caused by
alterations that do not involve the primary nucleotide
sequence.1,2 Epigenetic changes include DNA methylation,
post-translational modiﬁcations of histone proteins, nucleo-
somal positioning, incorporation of histone variants, and the
action of non-coding RNAs [such as micro (mi)RNAs].3 The
‘classical’ epigenetic effect occurs when epigenetic silencing
of one allele acts in concert with an inactivating mutation in
the opposite allele, resulting in total allelic loss; for example,
hypermethylation and deletion of the BRCA1 promoter in
sporadic breast cancer.4
The tumour microenvironment (TME) also represents an
important source of epigenetic regulation of the epithelial
compartment in breast cancer. As well as harbouring malig-
nant cells, the TME contains cells of mesenchymal and
haematopoietic origin and non-cellular components.5 Cells of
mesenchymal origin in the TME include ﬁbroblasts,3025/Online ISSN 1465-3931 © 2016 Royal College of P
er the CC BY license (http://creativecommons.org/licenses
i.org/10.1016/j.pathol.2016.10.009myoﬁbroblasts, mesenchymal stem cells (MSCs), adipocytes,
and endothelial cells, while cells of haematopoietic origin
include lymphoid cells [T cells, B cells, and natural killer (NK)
cells] and myeloid cells [macrophages, neutrophils, and
myeloid-derived suppressor cells (MDSCs)]. The non-cellular
component is the extracellular matrix (ECM) formed by the
basement membrane and interstitial matrix (consisting of
collagens, proteoglycans, and glycoproteins) (Fig. 1).
The TME also has an important metabolic (pH, PO2,
glucose, glutamine, lactate) and chemical (e.g., nitric oxide)
environment.6 This is further discussed by Simmons et al. in
this issue.7 Experimental modelling has shown that epige-
netic cross-talk between cells in the TME drives the efﬁ-
ciency of cancer formation, the rate of cancer growth, the
extent of invasion, the ability of cancers to metastasise, and
their response to treatments.8
CANCER-ASSOCIATED FIBROBLASTS IN
THE TME
What are cancer-associated ﬁbroblasts?
Fibroblasts are generally the most abundant cell type in the
TME. A subpopulation of ﬁbroblasts known as cancer-
associated ﬁbroblasts (CAFs) is thought to be of critical
importance in cancer initiation, progression, survival,
metastasis, and invasion via the secretion of various growth
factors, cytokines, and chemokines and the degradation of
ECM proteins.9,10 The origins of CAFs in breast cancer
stroma are diverse.10 The vast majority are thought to arise
from normal ﬁbroblasts, and breast cancer cells are known to
induce epigenetic changes in normal ﬁbroblasts that trans-
form them into CAFs. For instance, Tyan et al.11 showed that
breast cancer cells can induce hepatocyte growth factor
(HGF) secretion by CAFs to enhance tumorigenesis and that
when normal ﬁbroblasts were cultured with the breast cancer
cell line MDA-MB-231 they secreted HGF and adopted a
CAF phenotype. In another example, the MCF-7 breast
cancer cell line was found to reduce caveolin-1 (Cav-1)
expression (a CAF biomarker) in normal ﬁbroblasts, resulting
in phenotype switching to CAFs and increased expression of
CAF-associated markers.12
CAFs also arise when epithelial cells undergo epithelial-
mesenchymal transition (EMT), from bone marrow-derived
stem cells that have undergone EMT, or from trans-
differentiated breast tissue cells such as pericytes, adipocytes,
or smooth muscle cells (Fig. 2).13,14 The CAF proﬁle differsathologists of Australasia. Published by Elsevier B.V. This is an open
/by/4.0/).
Fig. 1 Components of the tumour microenvironment (TME). The TME is a complex mixture of not only carcinoma cells but also many cells of different lineages and
extra-cellular material. The cellular component includes cells of mesenchymal origin [ﬁbroblasts, cancer-associated ﬁbroblasts (CAFs), myoﬁbroblasts, mesenchymal
stem cells (MSCs), adipocytes, and endothelial cells] and those of haematopoietic origin: lymphoid cells [T cells, B cells, and natural killer (NK) cells] and myeloid cells
(macrophages), neutrophils, and myeloid-derived suppressor cells (MDSCs). The non-cellular component is the extracellular matrix (ECM). The TME is an important
epigenetic regulator of the epithelial compartment in breast cancer that ultimately inﬂuences the cancer phenotype.
134 MCCUAIG et al. Pathology (2017), 49(2), Februarydepending on the TME and breast cancer subtype. In general,
CAFs highly express a-SMA, p53, podoplanin, CD10,
ﬁbroblast activation protein (FAP), matrix metalloproteinases
(MMPs), tenascin-C, and platelet-derived growth factor
(PDGFRa/b) and lose Cav-1 expression.10,12 Cytoskeleton-
and integrin signalling-associated genes are up-regulated in
HER2+ breast cancers compared to triple-negative breast
cancers.15 However, a universal CAF ‘signature’ has so far
proven elusive.10
The gene expression proﬁles of ﬁbroblasts from women
without breast cancer have been compared to those from
women with breast cancer.16 Many genes are up-regulated in
CAFs compared to normal ﬁbroblasts including growth fac-
tors [ﬁbroblast growth factors (FGFs), hepatocyte growth
factor (HGF), transforming growth factor beta (TGF-b), and
stromal cell-derived factor 1 (SDF-1)], cytokines [granulocyteFig. 2 Potential origins of cancer-associated ﬁbroblasts (CAFs). There are multiple sour
ﬁbroblasts under the inﬂuence of epigenetic signalling from breast cancer cells (non-stem
epithelial-mesenchymal transition (epithelial cells), transdifferentiated pericytes, adipoc
inﬂuenced pathways induce epigenetic changes that promote a CAF proﬁle.macrophage colony-stimulating factor (GM-CSF), effector
cell protease receptor 1 (EPR-1)], oncoproteins (K-ras), reg-
ulators of gene expression (nuclear-encoded mitochondrial
elongation factor Ts, ribosomal protein S12, and spliceosome-
associated protein SAP 145), and a variety of other genes
associated with the cell cycle, cell-cell interactions, and cell-
cell communication. Many of these gene products are pro-
invasive and pro-metastatic.10,17
Breast cancer CAFs also show aberrations in DNA
methylation, histone modiﬁcations, and dysregulated
miRNAs.18 While all DNA is coated with methyl moieties,
the DNA methylation pattern is regulated by an independent
enzymatic process catalysed by DNA methyltransferases
(DNMTs). In terms of DNA methylation, the DNA methyl-
ation proﬁles of 143 human breast tumours showed signiﬁ-
cant differences in HER2 expression and DNA methylationces of CAFs, with the vast majority arising from phenotypic switching of normal
-like carcinoma cells and cancer stem cells). However, CAFs can also arise from
ytes, or smooth muscle cells, and bone marrow-derived stem cells. These TME-
TME IN BREAST CANCER 135of ﬁve genes, three of which were also methylated in the
tumour stroma as well as the cancer cells.19 Furthermore,
methylation-speciﬁc digital karyotyping revealed epigenetic
alterations in stromal ﬁbroblasts as well as epithelial and
myoepithelial cells in normal breast tissues compared to in
situ and invasive carcinomas.18
DNA is normally wrapped around histones, thereby
providing another important mechanism of gene regulation.
Loss of histone deacetylase 1 (HDAC1) expression has been
shown to increase osteopontin glycoprotein expression
within the stromal compartment of invasive breast cancers,
which then activates CAFs to promote tumour growth
in vivo.20 MicroRNAs (miRNAs) are a class of short non-
coding regulatory RNAs involved in stem cell maintenance,
developmental programming, cell fate speciﬁcation, and
various pathologies, not least cancer. Depending on the
protein targeted, miRNAs can act as either oncogenes or
tumour suppressors. miRNAs have been shown to be
dysregulated in breast CAFs; in particular, miR-200s are
down-regulated in activated CAFs in breast cancer tissues.21
Breast CAFs can induce EMT in breast cancer cells and
the cancer stem cell phenotype
The process of EMT confers mesenchymal properties on
epithelial cells that are closely associated with the acquisition
of aggressive traits seen in the cancer stem cell (CSC)
phenotype.22 Furthermore, such CSCs have been shown to
resist standard anticancer therapies.23 Several studies have
shown that breast CAFs can induce an EMT signature
(including increased vimentin expression and decreased E-
cadherin expression) in breast cancer cells (Fig. 3).23–25 For
example, non-CSCs [also known as non stem-like cancer
cells (NSCs)] derived from human mammary basal epithelial
cells (HMECs) maintain the ZEB1 promoter, a key regulator
of EMT transition, in a bivalent chromatin conﬁguration.26
Bivalency in this context refers to chromatin existing in a
repressed state but poised for rapid transcriptional activation
in response to signalling cues that favour differentiation; this
enables them to switch to a stem cell-like state. In the bivalent
state, the ZEB1 promoter is marked with both activeFig. 3 The role of cancer-associated ﬁbroblasts (CAFs) in breast cancer epithelial-mese
in Fig. 2, CSCs can induce epigenetic changes in ﬁbroblasts to create a CAF phenotyp
carcinoma cells through secretion of TGF-b and IL-1b into the tumour microenvironme
CAFs interacting with carcinoma cells to induce transition of the non-stem-like carcino
the acquisition of the mesenchymal CSC phenotype that favours breast cancer cell mig(H3K4me3) and repressive (H3K27me3) histones. In
response to microenvironmental signals such as TGF-b, a
well-known EMT inducer, released by CAFs, the ZEB1
promoter converts to an active chromatin conﬁguration (with
loss of H3K27me3), ZEB1 transcription increases, and non-
CSCs enter the CSC state. These CSCs can self-renew and
drive tumorigenesis. Breast CSCs display a CD44+/CD24–
cell surface marker proﬁle and are also known to form a
subpopulation of circulating tumour cells that might give rise
to metastases. CAFs, through increased expression of the
chemokine CCL2 via NOTCH1-STAT3 activation, have
been shown to stimulate the CSC phenotype in breast cancer
cells and inhibition of CCL2 in ﬁbroblasts in xenograft
models of breast cancer abrogates this tumorigenic effect.27
De Marco et al.28 recently showed that CAFs mediate the
malignant phenotype and cancer aggressiveness through
secretion of IL-1b into the TME and its consequent effect on
breast cancer cells, as IL-1b drives a pro-tumorigenic in-
ﬂammatory phenotype via the IL1R1 receptor on cancer cells.
The G-protein oestrogen receptor (GPER) triggers up-
regulation of IL-1b and ILIR1 expression on CAFs and
breast cancer cells, respectively, to promote breast cancer cell
migration and invasion.28 The relationship between EMT and
epithelial CSCs indicates that EMT is thus particularly
dangerous since, by imparting mesenchymal traits to carci-
noma cells, EMT can generate properties associated with
high-grade malignancy including motility, invasion, resis-
tance to apoptosis, and metastasis.22
CAFs and their effect on other components of the
microenvironment
CAFs are also known to mediate a tumour-enhancing in-
ﬂammatory proﬁle driven by NF-kB, which promotes
angiogenesis and tumour growth via the release of growth
factors (FGFs, HGF, TGF-b, SDF1), cytokines (CXCL12,
IL-6), and hormones (such as oestrogen) in the TME.29–33
CAFs can attract immunosuppressive cells (for example,
FOXP3 T cells and myeloid-derived suppressor cells) to the
TME that inhibit T cell function and suppress adaptive im-
munity and natural killer cell function.34,35 CAF eliminationnchymal transition (EMT) and the cancer stem cell (CSC) phenotype. As shown
e. In this context, CAFs can induce a CSC proﬁle in non-stem-like epithelial
nt (initiating EMT) and/or via increased expression of the chemokine CCL2 by
ma cells (NSCs) to a more mesenchymal state. Both of these pathways increase
ration, invasion, and resistance to therapy.
136 MCCUAIG et al. Pathology (2017), 49(2), Februaryhas been shown to reduce tumour-associated macrophages
and myeloid-derived suppressor cell recruitment to tu-
mours.36 CAFs have also been shown to depress the Th1
immune response by suppressing Th1 cytokines and
enhancing an immunosuppressive Th2 cytokine signature
and tumour growth in CAF-knockout cancer metastasis
models in vivo.36
OTHER MESENCHYMAL COMPONENTS OF
THE TME AND BREAST CANCER
Adipocytes and endothelial cells in the TME
Other cells of mesenchymal origin in the TME include adi-
pocytes and endothelial cells. The concept that adipocytes
participate in cancer initiation, growth, and metastasis is now
called ‘adiponcosis’.37 For example, the release of CC-
chemokine ligand 5 (CCL5) by adipocytes has been shown
to promote the motility and invasion of triple-negative breast
cancer cells.38 The secretion of factors such as leptin and
interleukin 6 (IL-6) by adipocytes has been shown to be
important in inducing breast cancer cell EMT and activating
CSC pathways.39 Furthermore, adipocytes have been shown
in vitro and in vivo to participate in a highly complex cycle
whereby breast cancer cells modify the phenotype of peri-
tumoral adipocytes that in turn modify the cancer cell
phenotype to promote cancer progression.40
In addition to the accepted roles of tumour blood and
lymphatic vessels as conduits for blood supply and tumour
dissemination, these vessels have also been shown to play an
important role in cancer cell crosstalk via molecules secreted
by the blood (BEC) and lymphatic (LEC) endothelial cells
(also called angiocrine and lymphangiocrine factors). BEC-
cancer cell crosstalk can induce stem cell-like properties
and EMT in cancer cells similar to CAFs.41 Lee et al.42
showed that triple-negative breast tumours induced LECs to
secrete CCL5, which recruits CCR5-expressing cancer cells
into the lymphatic system, thereby promoting lymph node
metastasis.
Haematopoietic cells of the TME
The cells of haematopoietic origin in the TME include
lymphoid cells (T cells, B cells, and NK cells) and myeloid
cells (macrophages, neutrophils, and MDSCs). A detailed
discussion of the role of tumour-inﬁltrating lymphocytes is
the subject of a number of detailed reviews including in this
edition and will not be discussed further.43,44
MDSCs are a heterogeneous population of immature
myeloid cells that inhibit innate and adaptive immunity and
suppress various immune cells such as T cells, dendritic cells,
and NK cells and stimulate immune modulators such as Th2
T cells, T regulatory cells (Treg), and tumour-associated
macrophages (TAMs). Increased MDSCs are closely corre-
lated with increased tumour burden and the duration of breast
cancer.45
NK cells are a major component of the antitumor immune
response and are involved in controlling tumour progression
and metastasis in animal models. Mamessier et al.46 showed
that NK cell dysfunction causes human breast cancer pro-
gression. Breast cancer cells appear to alter NK cell function
by modulating their surface receptors, and several stroma-
derived factors including TGF-b1 in the TME are involved
in a tumour-induced reduction in normal NK cell function.46The ECM of the TME
The ECM constitutes the non-cellular component of the TME
and includes the basement membrane and interstitial matrix
(consisting of collagens, proteoglycans, and glycoproteins).
There is good evidence to suggest that proteoglycan/glycos-
aminoglycan expression levels and ﬁne structures are
involved in breast cancer growth, invasion, and metastasis.
For example, the proteoglycan versican has been shown to
stimulate mesenchymal-epithelial transition (MET) and in-
crease breast cancer cell proliferation at metastatic sites.47
DNA methylation also plays an important role in regulating
collagens in cancer.48 Chernov et al.49 showed in MCF-7
breast cancer cells that certain collagen genes are epigeneti-
cally silenced by H3K27me3 repression, which changes the
ECM composition to an invasion-promoting collagen-
enriched matrix.49
The roles of various elements of the TME and their role in
breast cancer are summarised in Fig. 4.
CONTRIBUTION OF THE TME TO
METASTASIS IN BREAST CANCER
Metastasis is an inefﬁcient process. For most breast cancers
only a minority of cancer cells successfully spread, colonise
and grow at a distant site.50 Metastasis is also dependent on
the metastatic niche, which describes the specialised micro-
environment that supports metastatic events and the envi-
ronment at distant metastatic sites.51 The metastatic niche
model proposes two mechanisms by which successful
metastasis might occur: through either a pre-existing niche or
an induced metastatic niche. A pre-existing niche is a site that
supports a pre-existing normal, speciﬁc physiological func-
tion that is then co-opted or hijacked by a metastatic cancer
cell to aid its survival in the new TME such as within bone
marrow.52 In contrast, an induced niche is present when there
have been changes to the nature of the microenvironment’s
ECM and component cells that are permissive to colonisation
by metastatic cells.52,53
The TME also plays a critical role in regulating metastatic
events in breast cancer.52,54,55 Metastasis is not a single event
but rather a complex series of events that includes the inva-
sive tumour cell growth, ECM degradation, and invasion into
the lymph or circulatory system. As noted above, tumour
cells must undergo EMT to acquire an invasive and mesen-
chymal phenotype, and CAFs—a primary component of the
breast cancer stroma—are signiﬁcant mediators of EMT and
metastasis.56 However, this is not their sole function, as CAFs
can also enhance invasion through active degradation of the
ECM via a diverse array of mediators including upregulation
of palladin (a cytoskeletal protein) and proteolytic en-
zymes.57 CAFs can also play a direct role in cancer metastasis
by leading the actual invasion and metastasis of tumour cells
from the site of the primary tumour.58
The niche colonised by cancer cells is an important part of
the metastatic process. The ability of metastases to thrive at
distant sites requires tumour cells to adapt to new and often
dramatically different microenvironments.59 Work by
Malanchi et al.54 demonstrated in a breast cancer model that
POSTN is a critical mediator expressed in primary tumour
stroma and that CSCs migrating to distant sites also need to
induce stromal POSTN so that the tumour cells can colonise
the new site. In this respect, the invading tumour cells alter
the new microenvironment to be more receptive to metastatic
Fig. 4 The various elements of the tumour microenvironment (TME) and their role in breast cancer. Breast non-stem-like cancer cells (NSCs) can, through paracrine
signalling, inhibit the expression of caveolin-1 (CAV-1) in normal ﬁbroblasts to promote a shift to a cancer-associated ﬁbroblast (CAF) signature. The CAFs then
increase expression of a variety of mediators that enhance tumorigenesis (coloured balls: red = HGF, blue = TGFb, orange = CCL2, green = IL6, yellow = IL1b,
purple = SDF-1, black = CXCL12). This drives EMT and induces the non-stem-like cancer cell ZEB1 promoter to lose its tri-methylation on H3K27 (inactive mark red
balls) and retain its active mark (green balls) H3K4me3, resulting in increasing chromatin accessibility of ZEB1 and transcription and allowing entry to the CSC
signature that enhances invasion, metastasis, and resistance to therapy. The new CSC can in turn induce the formation of more CAF signature cells, resulting in feedback
that increases overall tumour malignancy. In addition to this pathway, CAFs can also arise from endothelial cell EMT and other transdifferentiated cells (blue square
cells). Adipocytes are also involved in this TME regulation (a process known as adiponcosis), contributing to tumorigenesis via EMT differentiation into CAFs to
enhance cancer growth, survival, and aggressiveness through the secretion of IL6 (pink balls) and CCL5 (light blue balls).
TME IN BREAST CANCER 137colonisation.54 Zhang et al.55 recently illustrated an elegant
example of tumour cell adaptation to a new TME in brain
metastasis, with tumour cells losing PTEN expression after
metastatic invasion of the brain but not other tissues and
organs. It was proposed that extracellular vesicles (EVs)
containing PTEN-blocking microRNAs may have mediated
this knockdown effect. EVs comprise a diverse range of
structures of different cellular origin and highly variable
‘cargo’ and include exosomes, microvesicles, and large
oncosomes,60 all of which can inﬂuence the TME. EVs can
reprogram cancer cell metabolism, mediate therapeutic drug
interactions, and are implicated in driving the transformation
of ﬁbroblasts and other TME cells to a CAF phenotype.61–63
EVs can in turn enhance the metastatic potential of
the tumour such as up-regulating MMP-9 expression in
melanoma cells and reprogramming cancer cells with
enhanced metastatic potential.64 Le et al.65 showed that EVs
containing miR-200 can alter gene programming and pro-
mote MET. Tumour metastasis is enhanced by the mesen-
chymal phenotype; however in many tumours, including
breast cancer, invading cells require epithelial traits to colo-
nise other sites. miR-200 can confer strong metastatic po-
tential to either adjacent cells or even tumour cells at distant
sites through this re-programming.65
THE TME AND THERAPEUTIC RESISTANCE
IN BREAST CANCER
Despite signiﬁcant improvements in outcomes for breast
cancer patients over the last 20 years, drug resistance and
tumour recurrences occur. The TME, and speciﬁcally CAFs,
are implicated in breast cancer resistance to therapy.14
Several authors have shown that CAFs play a signiﬁcant
role in tamoxifen resistance through activation of the PI3K/
AKT and MAPK/ERK pathways and induction of the
oestrogen receptor (ER) via the G protein-coupled ER topromote proliferation and progression of breast cancer
cells.66–68 Furthermore, Yuan et al.69 demonstrated that the
G protein-coupled ER GFR/ERK pathway increases b1-
integrin expression to contribute to CAF-associated EMT,
invasion, and tamoxifen resistance in MCF-7 breast cancer
cells.69 Mao et al.70 recently demonstrated that CAFs can
render HER2+ breast cancer cells resistant to trastuzumab via
IL-6 and the activation of multiple pathways including NF-
kB, JAK/STAT3, and PI3K/AKT.70 Farmer et al.71 demon-
strated that very desmoplastic stroma in breast cancer pro-
duces a stromal gene expression that predicts resistance to
pre-operative chemotherapy.71 The TME, and in particular
the CAFs and immune cells, are also thought to play a role in
radiotherapy resistance.72 As various immunotherapies are
introduced in breast cancer management, it is likely that both
intrinsic but acquired therapeutic resistance will occur in the
TME as reported in other cancers.73
THERAPEUTIC TARGETING OF THE TME
USING EPIGENETIC DRUGS
The current standard treatment for breast cancer includes
surgery, radiotherapy, chemotherapy and hormone therapy.
The treatment given largely depends on the pathological
characteristics of the breast cancer, the clinical stage of dis-
ease, and the age and general health of the patient. One of the
potentially most attractive new therapies is targeting epige-
netic inheritance because, in contrast to DNA mutations,
these defects are passively inherited and thus must be actively
maintained because they are reversible. Re-expression of
genes epigenetically inactivated can suppress the disease
state or sensitise to speciﬁc therapies. Small molecules that
reverse epigenetic inactivation, so-called ‘epi-drugs’, are now
undergoing clinical trials. To date, most epi-drug studies have
focused on the direct treatment of the epithelial cell
compartment rather than the TME. The best-studied
138 MCCUAIG et al. Pathology (2017), 49(2), Februaryepigenetic drugs are the histone modiﬁers. Histones are
modiﬁed by histone-modifying enzymes that add or remove
covalent moieties to histone proteins.74 Among these, histone
acetyl transferases (HATs) act as ‘writers’ that transfer acetyl
groups to lysine residues on histones to activate transcription,
and histone deacetylases (HDACs) act as ‘erasers’ that
remove acetyl groups to repress gene transcription.75 The
term ‘HDAC inhibitors’ refers to a group of compounds that
target this latter mechanism, and these drugs have been tested
in breast cancer clinical trials.76,77 DNA methyltransferase
(DNMT) inhibitors are another group of epigenetic drugs that
have been shown to inhibit cell growth and work well in
combination with HDAC inhibitors. Furthermore, some
DNMT inhibitors have been shown to re-express functional
ER in ER negative breast cancer cells in which the ER has
been epigenetically silenced.78 Both DNMT and HDAC in-
hibitors have been shown to re-express epigenetically
silenced genes in breast cancer and improve patient out-
comes; however, long-term efﬁcacy is limited and very high
doses are often required, suggesting that combination stra-
tegies to enhance responses are important.76,79
Epigenetic modifying agents have been shown to ‘prime’
the immune system, making combination therapy with
immune modulators attractive. Kim et al.80 showed that 5-
azacytidine (5-AZA; a DNA methyltransferase inhibitor) in
combination with anti PD-1 and anti CTLA-4 monoclonal
antibodies eradicated both primary and metastatic tumours in
mice.80 5-AZA has also been shown to up-regulate genes
responsible for antigen processing and presenting [such as
tumour-associated antigens, major histocompatibility com-
plex proteins, co-stimulatory molecules (e.g., CD40, CD80,
CD86, ICAM-1)] and death-inducing receptors that targetFig. 5 New classes of epigenetic therapeutic targets in breast cancer. (A) The role of PK
in the context of chromatin-tethered kinases and epigenetic enzymes. Previous research
of PKC-q via TGF-b and inﬂammatory signals (e.g., IL6, TNF-a and EGF) phosphoryla
q to the chromatin template to recruit RNA polymerase II (RNA POL II) and subsequen
activation has been shown to have a critical role in the dephosphorylation of P300 at s
enhancers. These key molecular mechanisms can be inhibited (see blue inhibitor boxe
dolylmaleimide I (BIM), or PKC-q siRNA] or NF-kB (with Bay11-7082 or NF-kB p5
High resolution 3D image of a mesenchymal breast cancer cell, clearly displaying thecancer cells (e.g., FAS), causing a shift in the balance of
immune inhibition towards immune activation.81
Recent studies by our laboratory (Zafar et al.82 and
Boulding et al.83) have identiﬁed potential new classes of
epigenetic therapeutic targets (Fig. 5). While protein kinase C
(PKCs) have long been recognised as cytoplasmic signalling
proteins, we and others have shown that PKCs belong to
an emerging class of kinases that have a dual function as
epigenetic enzymes.84–86 These chromatin-tethered kinases
modulate chromatin structure to make it conducive for
active transcription by two distinct mechanisms: (1) structural
(as part of transcription complexes) and (2) enzymatic (by
phosphorylating key nucleosome components, the basic
unit of chromatin).82 Our ﬁndings have shown that PKC-theta
(PKC-q) is a signalling kinase that is speciﬁcally targeted to
the nucleus to function as a transcriptional regulator by
tethering to the epigenome; PKC-q is also a critical molecular
mediator of CSC function. This nuclear kinase mediates
crosstalk between extracellular signals and the epigenome in
breast CSCs in response to TGF-b and inﬂammatory signals
mediated via the NF-kB pathway in breast cancer.82 In
particular, our genome-wide PKC-q chromatin immunopre-
cipitation (ChIP)-sequencing analysis identiﬁed direct PKC-
q-dependent targets in CSCs, with well-established master
CSC regulators represented in the target geneset.82 This novel
nuclear PKC-q epigenetic mechanism in human CSCs shows
that active nuclear PKC-q is critical for mediating open/
permissive chromatin regulatory regions and is essential for
the transcription of key CSC-enriched genes. Our ﬁndings
show that targeting PKC-q with selective inhibitors such as
C27 or siRNA abrogates breast CSCs. Furthermore, dual-
speciﬁcity phosphatases (DUSPs), which dephosphorylateC-theta (PKC-q), DUSPs, and NF-kB in the biology of cancer stem cells (CSCs)
from the Rao Laboratory demonstrated that, in the mesenchymal state, activation
tes NF-kB (p50:p65) for translocation to the nucleus, where NF-kB tethers PKC-
t transcription of CSC-inducible genes. In addition, together with PKC-q, DUSP
erine 89, which can further activate H3K27 acetylation at CSC repressive gene
s) by blocking the epigenetic kinase PKC-q [with compound 27 (C27), bisin-
0/p65 siRNA) or DUSP1 (with NSC 95397, triptolide, or DUSP1 siRNA). (B)
nuclear bias of the epigenetic kinase PKC-q in this cell.
TME IN BREAST CANCER 139threonine/serine and tyrosine residues on their substrates, are
involved in EMT and breast CSC regulation and are induced
during EMT in a PKC pathway signal-mediated EMT
model.83 Hence, given that CSCs mediate the transition to
CAFs in breast cancer, we postulate that targeting this novel
PKC-epigenetic axis may offer new therapeutic avenues to
simultaneously eliminate CAFs and CSCs in breast cancer.
Given the importance of TGF-b and NF-kB in CAF-mediated
tumorigenesis,29,87 PKC-q may also have a direct epigenetic
role in CAFs that needs to be elucidated. PKCs belong to a
family of 11 isoforms (conventional, atypical, and novel), and
the interplay between these kinases, CAFs, and CSCs also
requires further investigation. It remains to be seen if thera-
peutic targeting of these enzymes will abrogate CAFs in
breast cancer in vivo.
Therefore, many components of the TME, particularly
those related to EMT activation in breast cancer cells and the
possible entry of these cells into the CSC state,5 could
potentially be targeted for cancer prevention and treatment as
part of epi-drug development. Treatments that normalise the
stroma are also potentially powerful therapeutic strategies.88
CONCLUSIONS
This review highlights that research into breast cancer
development, progression, and management can no longer
focus solely on malignant breast epithelial cells but also
needs to address the role of the TME both in the primary
cancer and in metastases. The role of the TME now needs to
be considered when assessing the impact of various treat-
ments. In the future, pathologists may need to map speciﬁc
epigenetic proﬁles of individual TME components as part of
the prognostic and predictive work-up of an individual cancer
and to guide precision therapy.
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